Clinical trials · source year
46 selected, source-linked clinical trial records dated 2023. This is selective source coverage, not a complete timeline.
46 selected records.
13 connected profiles.
46 distinct public records.
Cited chronology
Exenatide
PeptideScanner retained ClinicalTrials.gov record NCT01524705 at 2026-07-30T19:03:45.487Z. Its registry update date was 2023-12-29, and PeptideScanner's reviewed identity mapping was exenatide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT03795701 at 2026-07-30T19:03:45.488Z. Its registry update date was 2023-12-04, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Octreotide
PeptideScanner retained ClinicalTrials.gov record NCT02381249 at 2026-07-30T19:04:52.219Z. Its registry update date was 2023-11-27, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Octreotide
PeptideScanner retained ClinicalTrials.gov record NCT02385617 at 2026-07-30T19:04:52.214Z. Its registry update date was 2023-11-27, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT00541047 at 2026-07-30T19:04:52.204Z. Its registry update date was 2023-11-13, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT06106932 at 2026-07-30T19:07:27.301Z. Its registry update date was 2023-10-30, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Pramlintide
PeptideScanner retained ClinicalTrials.gov record NCT05199714 at 2026-07-30T19:07:27.301Z. Its registry update date was 2023-10-25, and PeptideScanner's reviewed identity mapping was pramlintide.
Source: ClinicalTrials.gov ↗
Afamelanotide
PeptideScanner retained ClinicalTrials.gov record NCT04525157 at 2026-07-30T19:08:50.172Z. Its registry update date was 2023-09-22, and PeptideScanner's reviewed identity mapping was afamelanotide.
Source: ClinicalTrials.gov ↗
Setmelanotide
PeptideScanner retained ClinicalTrials.gov record NCT02896192 at 2026-07-30T19:08:50.175Z. Its registry update date was 2023-09-21, and PeptideScanner's reviewed identity mapping was setmelanotide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT04263415 at 2026-07-30T19:08:50.175Z. Its registry update date was 2023-09-08, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT03737240 at 2026-07-30T19:08:50.174Z. Its registry update date was 2023-09-08, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT00002889 at 2026-07-30T19:09:38.368Z. Its registry update date was 2023-08-18, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT04026256 at 2026-07-30T19:09:38.366Z. Its registry update date was 2023-08-02, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT03936049 at 2026-07-30T19:10:42.712Z. Its registry update date was 2023-07-27, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT04879420 at 2026-07-30T19:10:42.715Z. Its registry update date was 2023-07-27, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT04897958 at 2026-07-30T19:10:42.712Z. Its registry update date was 2023-07-27, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Exenatide
PeptideScanner retained ClinicalTrials.gov record NCT03331289 at 2026-07-30T19:10:42.713Z. Its registry update date was 2023-07-24, and PeptideScanner's reviewed identity mapping was exenatide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT03374956 at 2026-07-30T19:10:42.750Z. Its registry update date was 2023-07-18, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT02527200 at 2026-07-30T19:10:42.748Z. Its registry update date was 2023-07-06, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Octreotide
PeptideScanner retained ClinicalTrials.gov record NCT00427349 at 2026-07-30T19:10:42.711Z. Its registry update date was 2023-07-05, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Lanreotide
PeptideScanner retained ClinicalTrials.gov record NCT03043664 at 2026-07-30T19:11:49.726Z. Its registry update date was 2023-06-29, and PeptideScanner's reviewed identity mapping was lanreotide.
Source: ClinicalTrials.gov ↗
Pramlintide
PeptideScanner retained ClinicalTrials.gov record NCT01841359 at 2026-07-30T19:11:49.725Z. Its registry update date was 2023-06-29, and PeptideScanner's reviewed identity mapping was pramlintide.
Source: ClinicalTrials.gov ↗
Octreotide
PeptideScanner retained ClinicalTrials.gov record NCT00003057 at 2026-07-30T19:11:49.726Z. Its registry update date was 2023-06-18, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Octreotide
PeptideScanner retained ClinicalTrials.gov record NCT00003283 at 2026-07-30T19:11:49.727Z. Its registry update date was 2023-06-15, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT04605861 at 2026-07-30T19:11:49.726Z. Its registry update date was 2023-06-07, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Octreotide
PeptideScanner retained ClinicalTrials.gov record NCT02333565 at 2026-07-30T19:13:03.754Z. Its registry update date was 2023-05-25, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Octreotide
PeptideScanner retained ClinicalTrials.gov record NCT02384122 at 2026-07-30T19:13:03.754Z. Its registry update date was 2023-05-24, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Setmelanotide
PeptideScanner retained ClinicalTrials.gov record NCT03287960 at 2026-07-30T19:13:03.752Z. Its registry update date was 2023-05-23, and PeptideScanner's reviewed identity mapping was setmelanotide.
Source: ClinicalTrials.gov ↗
Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT03072147 at 2026-07-30T19:13:03.748Z. Its registry update date was 2023-05-12, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT01779362 at 2026-07-30T19:13:03.753Z. Its registry update date was 2023-05-11, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Glucagon
PeptideScanner retained ClinicalTrials.gov record NCT04859322 at 2026-07-30T19:13:03.753Z. Its registry update date was 2023-05-11, and PeptideScanner's reviewed identity mapping was glucagon.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT02058706 at 2026-07-30T19:13:03.747Z. Its registry update date was 2023-05-10, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Exenatide
PeptideScanner retained ClinicalTrials.gov record NCT01416649 at 2026-07-30T19:14:02.187Z. Its registry update date was 2023-04-26, and PeptideScanner's reviewed identity mapping was exenatide.
Source: ClinicalTrials.gov ↗
Afamelanotide
PeptideScanner retained ClinicalTrials.gov record NCT04962503 at 2026-07-30T19:14:02.188Z. Its registry update date was 2023-04-11, and PeptideScanner's reviewed identity mapping was afamelanotide.
Source: ClinicalTrials.gov ↗
Abaloparatide
PeptideScanner retained ClinicalTrials.gov record NCT03512262 at 2026-07-30T19:14:02.186Z. Its registry update date was 2023-04-07, and PeptideScanner's reviewed identity mapping was abaloparatide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT04172987 at 2026-07-30T19:15:14.513Z. Its registry update date was 2023-03-27, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT03940742 at 2026-07-30T19:15:14.510Z. Its registry update date was 2023-03-24, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT00001259 at 2026-07-30T19:15:14.515Z. Its registry update date was 2023-03-02, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT03043807 at 2026-07-30T19:16:22.177Z. Its registry update date was 2023-02-16, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Abaloparatide
PeptideScanner retained ClinicalTrials.gov record NCT04064411 at 2026-07-30T19:16:22.171Z. Its registry update date was 2023-02-15, and PeptideScanner's reviewed identity mapping was abaloparatide.
Source: ClinicalTrials.gov ↗
Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT04589819 at 2026-07-30T19:16:22.171Z. Its registry update date was 2023-02-13, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Afamelanotide
PeptideScanner retained ClinicalTrials.gov record NCT05368857 at 2026-07-30T19:16:22.169Z. Its registry update date was 2023-02-09, and PeptideScanner's reviewed identity mapping was afamelanotide.
Source: ClinicalTrials.gov ↗
Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT03472846 at 2026-07-30T19:17:35.707Z. Its registry update date was 2023-01-26, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Abaloparatide
PeptideScanner retained ClinicalTrials.gov record NCT03746041 at 2026-07-30T19:17:35.680Z. Its registry update date was 2023-01-23, and PeptideScanner's reviewed identity mapping was abaloparatide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT02967757 at 2026-07-30T19:17:35.705Z. Its registry update date was 2023-01-20, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT02440581 at 2026-07-30T19:17:35.692Z. Its registry update date was 2023-01-05, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗